PMS - MGH Center for Women's Mental Health

Will PMDD Have a New Home in the DSM-V?

The American Psychiatric Association is now considering the possibility of including premenstrual dysphoric disorder (PMDD) in the DSM-V as a new category, rather than listing a set of criteria for PMDD in the appendix (as in DSM-IV). The diagnostic criteria remain relatively unchanged. Many feel that the Inclusion of PMDD as a distinct diagnostic category will lead to greater legitimacy for the disorder and will encourage the growth of evidence-based research in this area.

By MGH Center for Women's Mental Health|2015-08-12T15:17:11-04:00June 1st, 2012|Diagnosis & Screening, PMS & PMDD|Comments Off

Yaz and Other Oral Contraceptives Will Carry a New Warning Label

The FDA will require Yaz, Yasmin and several other newer oral contraceptives to carry new warning labels that detail the potential risk of venous thromboembolism (VTE or blood clots). All oral contraceptives increase the risk of blood clots; however, recent studies have suggested that birth control pills containing drospirenone, a synthetic form of the hormone progesterone, may carry a slightly increased risk of VTE, compared with older birth control pills. The FDA estimates that over a one year period, 10 in 10,000 women taking an oral contraceptive with drospirenone would develop a blood clot , as compared to about 6 in 10,000 women taking older contraceptives.

By MGH Center for Women's Mental Health|2015-08-12T15:27:01-04:00May 24th, 2012|Contraception, General, Hormone Therapy|Comments Off

Premenstrual Syndromes: What is the Optimal Duration of Treatment?

Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) affect a large number of women of childbearing age. 30-80% of reproductive age women experience premenstrual symptoms. PMS refers to a pattern of physical, emotional, and behavioral symptoms occurring 1-2 weeks before menses and remitting with the onset of menses. Common symptoms include fatigue, poor concentration, mild mood changes, headaches, abdominal bloating, and breast tenderness.

By MGH Center for Women's Mental Health|2015-08-12T15:32:28-04:00December 21st, 2009|Medication, PMS & PMDD, Treatment|Comments Off

Cognitive Behavioral Therapy for Premenstrual Syndromes: A Review of the Literature

Significant numbers of reproductive-aged women experience premenstrual syndromes characterized by depressed mood, irritability, mood swings, anxiety or tension, sleep disruption, and other physical symptoms, including bloating and breast tenderness. Typically these symptoms emerge during the week preceding menstruation, improve with the onset of menses, and are not present during the week after menstruation.

By MGH Center for Women's Mental Health|2015-08-12T14:18:14-04:00April 6th, 2009|PMS & PMDD, Psychotherapy, Treatment|Comments Off

Bipolar Disorder and PMS

Premenstrual worsening of mood is common among women with depression, but little is known about how often women with bipolar disorder experience worsening of their mood premenstrually. In a study by Payne et al. (2007), premenstrual symptoms were reported by twice as many women diagnosed with mood disorders (mixture of Bipolar Disorder and Major Depressive Disorder) than by women who did not have a psychiatric diagnosis (67.7% vs. 33.7%). These results suggest that PMS symptoms are particularly common in women with bipolar disorder and major depressive disorder. However, this study involved women reporting prior experiences with PMS, which is not always as accurate as studies that involve prospective monitoring to obtain real-time reporting of PMS symptoms. Such prospective studies of PMS in women with bipolar disorder are sparse and have inconsistent conclusions.

By MGH Center for Women's Mental Health|2016-03-28T13:38:38-04:00December 15th, 2008|Bipolar Disorder, Diagnosis & Screening, PMS & PMDD, Prevalence & Risk Factors|Comments Off

Do Oral Contraceptives Cause Mood Changes?

Many women have concerns about the side effects of oral contraceptives (birth control pills). Potential side effects include bloating, breast tenderness, and weight gain. In addition, some women may experience depression or mood swings, side effects that may influence a woman’s decision to start taking a birth control pill, particularly if she has a history of depression.

By MGH Center for Women's Mental Health|2015-08-11T12:44:52-04:00May 1st, 2008|Contraception, Depressive Disorders, General|Comments Off

New Research Study at CWMH: Treatment of Premenstrual Worsening of Depression

Seeking women between 18-45 with PMS who have been diagnosed with depression. If you are between 18 and 45 and:

By MGH Center for Women's Mental Health|2015-08-11T10:15:59-04:00February 15th, 2008|PMS & PMDD, Research at CWMH, Treatment|Comments Off

Nutritional Supplements for Premenstrual Syndrome: Do They Work?

Many promote the use of certain vitamins and minerals for the treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), but controlled studies supporting the use of nutritional supplements are sparse.

By MGH Center for Women's Mental Health|2015-07-28T11:22:36-04:00January 24th, 2008|Alternative & Complementary, PMS & PMDD, Treatment|Comments Off

Oral Contraceptives for the Treatment of Premenstrual Mood Symptoms

Oral contraceptives are commonly prescribed for the treatment of premenstrual symptoms and premenstrual dysphoric disorder (PMDD); however, the evidence supporting the use of oral contraceptives in this setting is limited. While most studies have shown that oral contraceptives are not effective for the treatment of premenstrual symptoms, there is preliminary evidence that a new oral contraceptive pill, Yaz, which contains low-dose estrogen and a novel progestin called drospirenone, may alleviate the symptoms of PMDD.

By MGH Center for Women's Mental Health|2015-07-28T10:57:47-04:00November 13th, 2007|Hormone Therapy, PMS & PMDD, Treatment|Comments Off

Two MGH Center for Women’s Mental Health Physicians Featured in Elle Magazine

Lee S. Cohen, MD, and Hadine Joffe, MD, MSc, shared their expertise in reproductive health and oral contraceptives (OC) for Elle magazine’s recent article, “Against the Flow.” The article discusses Lybrel, the first continuous OC approved by the Food and Drug Administration (FDA). This new birth control pill has received attention because its continual low dose of estrogen and progestin completely eliminates monthly bleeding in women. It is 98 percent effective in preventing pregnancy, provides long-term health benefits, and eliminates what many women consider the “hassles” of menstruation.

By MGH Center for Women's Mental Health|2015-07-28T10:25:07-04:00September 28th, 2007|General|Comments Off